Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

SRR23036897

—

476c4187-c453-5c0b-8111-8ebb63acd8c1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.370
  • INTERFERON_GAMMA_RESPONSE+0.350
  • PROTEIN_SECRETION+0.330
  • ANDROGEN_RESPONSE+0.310
  • TGF_BETA_SIGNALING+0.310
  • TNFA_SIGNALING_VIA_NFKB+0.310
  • PI3K_AKT_MTOR_SIGNALING+0.300
  • MITOTIC_SPINDLE+0.280
  • APICAL_SURFACE+0.260
  • ESTROGEN_RESPONSE_EARLY+0.220

Top 10 suppressed

  • ANGIOGENESIS-0.480
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
  • MYC_TARGETS_V1-0.350
  • MYC_TARGETS_V2-0.280
  • OXIDATIVE_PHOSPHORYLATION-0.270
  • PANCREAS_BETA_CELLS-0.250
  • SPERMATOGENESIS-0.250
  • E2F_TARGETS-0.210
  • MYOGENESIS-0.200
  • DNA_REPAIR-0.170

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-UY-A9PA-01A-11R-A38B-07
bladder-landscape@3
——0.846
2MNG650
mng-umap@100
——0.779
3TCGA-CQ-6223-01A-11R-1915-07
head-neck@1
——0.754
4SRR10900584
melanoma-umap@29
——0.746
5MNG667
mng-umap@100
——0.744
6TCGA-CR-6492-01A-12R-2081-07
head-neck@1
——0.731
7TCGA-CV-7427-01A-11R-2081-07
head-neck@1
——0.728
8SRR23036887
head-neck@1
——0.717
9TCGA-05-4433-01A-22R-1858-07
lung-landscapes@6
—cohortA10.714
10b35a4a43-866d-4781-a4a8-9e2e728202ba
melanoma-umap@29
——0.703

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 30 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.370Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.350Idelalisib— uncovered
PROTEIN_SECRETION0.330Remibrutinib— uncovered
ANDROGEN_RESPONSE0.310Inavolisib— uncovered
TGF_BETA_SIGNALING0.310Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.310Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.300Inavolisib— uncovered
MITOTIC_SPINDLE0.280Inavolisib— uncovered
APICAL_SURFACE0.260Temsirolimus— uncovered
ESTROGEN_RESPONSE_EARLY0.220Inavolisib— uncovered
NOTCH_SIGNALING0.220Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.200Idelalisib— uncovered
ALLOGRAFT_REJECTION0.180Idelalisib— uncovered
PEROXISOME0.180Idelalisib— uncovered
APOPTOSIS0.170Idelalisib— uncovered
HEME_METABOLISM0.160Temsirolimus— uncovered
IL6_JAK_STAT3_SIGNALING0.150Inavolisib— uncovered
FATTY_ACID_METABOLISM0.140Inavolisib— uncovered
IL2_STAT5_SIGNALING0.140Idelalisib— uncovered
UV_RESPONSE_UP0.140Idelalisib— uncovered